AQR Capital Management
STRO icon

AQR Capital Management’s Sutro Biopharma STRO Stock Holding History

AQR Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$214K Sell
8,605
-9,429
-52% -$170K ﹤0.01% 3569
2025
Q4 		$209K Sell
18,034
-17,411
-49% -$165K ﹤0.01% 3347
2025
Q3 		$308K Sell
35,445
-65,827
-65% -$560K ﹤0.01% 3069
2025
Q2 		$723K Sell
101,272
-30,820
-23% -$252K ﹤0.01% 2400
2025
Q1 		$859K Buy
132,092
+120,633
+1,053% +$1.9M ﹤0.01% 2126
2024
Q4 		$211K Sell
11,459
-21,095
-65% -$644K ﹤0.01% 2656
2024
Q3 		$1.13M Buy
32,554
+4,202
+15% +$165K ﹤0.01% 1776
2024
Q2 		$831K Buy
28,352
+24,770
+692% +$979K ﹤0.01% 1835
2024
Q1 		$202K Sell
3,582
-4,781
-57% -$211K ﹤0.01% 2249
2023
Q4 		$359K Buy
8,363
+5,987
+252% +$190K ﹤0.01% 2003
2023
Q3 		$82.4K Sell
2,376
-5,794
-71% -$252K ﹤0.01% 2248
2023
Q2 		$380K Sell
8,170
-31,200
-79% -$1.55M ﹤0.01% 1864
2023
Q1 		$1.82M Buy
39,370
+19,559
+99% +$1.24M ﹤0.01% 1297
2022
Q4 		$1.6M Buy
19,811
+603
+3% +$41.9K ﹤0.01% 1354
2022
Q3 		$1.07M Buy
19,208
+13,268
+223% +$785K ﹤0.01% 1493
2022
Q2 		$309K Buy
5,940
+3,622
+156% +$202K ﹤0.01% 1860
2022
Q1 		$191K Buy
+2,318
New +$221K ﹤0.01% 2074
2021
Q4 		– Sell
-1,452
Closed -$274K – 2274
2021
Q3 		$274K Buy
+1,452
New +$276K ﹤0.01% 2060
2021
Q2 		– Sell
-4,267
Closed -$971K – 2296
2021
Q1 		$971K Buy
4,267
+2,766
+184% +$656K ﹤0.01% 1563
2020
Q4 		$326K Buy
+1,501
New +$249K ﹤0.01% 1943

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AQR Capital Management's STRO Position: Q1 2026 in Review

AQR Capital Management reduced its Sutro Biopharma (STRO) stake by 52% in Q1 2026, selling an estimated $170K and leaving 8,605 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #3569.

AQR Capital Management first reported a position in STRO in Q4 2020 and has held it in 20 quarters since. The position peaked at $1.82M in Q1 2023. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • AQR Capital Management held 8,605 shares of Sutro Biopharma worth $214K as of Q1 2026.
  • AQR Capital Management sold 9,429 Sutro Biopharma shares in Q1 2026, an estimated $170K.
  • Sutro Biopharma made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3569 holding.
  • AQR Capital Management first reported a position in Sutro Biopharma in Q4 2020 and has held it in 20 quarters since.
  • AQR Capital Management's Sutro Biopharma position peaked at $1.82M in Q1 2023.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.